Autopsy report · NCT01372228

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

“company did not pursue this indication”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 5 years before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Talaris Therapeutics Inc.

Sponsor type

Industry

Conditions

Hurler Syndrome (MPS I); Hurler-Scheie Syndrome; Hunter Syndrome (MPS II); Sanfilippo Syndrome (MPS III); Krabbe Disease (Globoid Leukodystrophy); Metachromatic Leukodystrophy (MLD)

Interventions

hematopoietic stem cell infusion

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
  “Development of indication not being pursued” (56% match in meaning)
• Diabetic Cardiomyopathy and Heart Failure
  “Did not receive funding as anticipated.” (55% match in meaning)
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
  “Study was terminated by Sponsor; the decision was not due to any safety findings.” (55% match in meaning)
• Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
  “This study was terminated early due to company decision. Part B was never conducted.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.